MAIA Biotechnology, Inc.

NYSEAM:MAIA Stock Report

Market Cap: US$52.9m

MAIA Biotechnology Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Vlad Vitoc

Chief executive officer

US$1.4m

Total compensation

CEO salary percentage33.1%
CEO tenureno data
CEO ownership4.4%
Management average tenureno data
Board average tenure3.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Vlad Vitoc's remuneration changed compared to MAIA Biotechnology's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$26m

Jun 30 2024n/an/a

-US$28m

Mar 31 2024n/an/a

-US$24m

Dec 31 2023US$1mUS$473k

-US$20m

Sep 30 2023n/an/a

-US$18m

Jun 30 2023n/an/a

-US$18m

Mar 31 2023n/an/a

-US$16m

Dec 31 2022US$1mUS$443k

-US$16m

Sep 30 2022n/an/a

-US$15m

Jun 30 2022n/an/a

-US$15m

Mar 31 2022n/an/a

-US$15m

Dec 31 2021US$703kUS$265k

-US$13m

Sep 30 2021n/an/a

-US$13m

Dec 31 2020US$1mUS$75k

-US$7m

Compensation vs Market: Vlad's total compensation ($USD1.43M) is above average for companies of similar size in the US market ($USD645.36K).

Compensation vs Earnings: Vlad's compensation has increased whilst the company is unprofitable.

CEO

Vlad Vitoc (54 yo)

no data

Tenure

US$1,430,757

Compensation

Dr. Vlad Vitoc, MD., MBA., is the Co-founder, Chairman, President and Chief Executive Officer of MAIA Biotechnology, Inc. Dr. Vitoc is a well-seasoned biotech executive with a broad array of experience acr...

Board Members

NamePositionTenureCompensationOwnership
Vlad Vitoc
Co-Founderno dataUS$1.43m4.42%
$ 2.3m
Ngar Louie
Independent Director4.7yrsUS$90.00k4.61%
$ 2.4m
Jerry Shay
Chairman of Scientific Advisory Board3.3yrsno datano data
Steven Chaouki
Independent Director3.3yrsUS$60.00k0.44%
$ 232.0k
Ramiro Guerrero
Independent Directorno dataUS$60.00k2.03%
$ 1.1m
Cristian Luput
Independent Directorno dataUS$60.00k1.54%
$ 814.0k
Stan Smith
Lead Independent Directorno dataUS$75.00k4.46%
$ 2.4m
David Ashley
Member of Scientific Advisory Board3.3yrsno datano data
Tudor Ciuleanu
Member of Scientific Advisory Board3.3yrsno datano data
Z. Dikmen
Member of Scientific Advisory Board3.3yrsno datano data
Adam Yopp
Member of Scientific Advisory Board3.3yrsno datano data
Jean-Manasse Theagene
Independent Director1.8yrsUS$47.50k0%
$ 0

3.3yrs

Average Tenure

57yo

Average Age

Experienced Board: MAIA's board of directors are considered experienced (3.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 04:13
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

MAIA Biotechnology, Inc. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hunter DiamondDiamond Equity Research LLC
Robert LeBoyerNOBLE Capital Markets, Inc.
Ashok KumarThinkEquity LLC